Retatrutide is currently progressing through Phase 3 clinical trials, and regulatory submission could be on the horizon if results continue to look promising. If approved, it could represent a transformative option for individuals with obesity or type 2 diabetes who have not achieved adequate results with existing treatments.https://retatrutide-peptide.nl/